Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint to Work With Mass University to Develop Ritalin-Like Compounds

NEW YORK, March 3 (GenomeWeb News) - DNAPrint Genomics will help the Massachusetts College of Pharmacy and Health Sciences develop Ritalin-like compounds, the company said today.


The research will be conducted under the supervision of Mark Froimowitz, a researcher at the Boston-based university, who recently licensed Ritalin analogs to DNAPrint. The compounds were developed as possible medications for drug abuse, attention deficit hyperactivity disorder, and depression.


DNAPrint will work with Froimowitz to develop theranostic tests based on the compounds, said Hector Gomez, DNAPrint's chairman and chief medical officer.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.